Browse > Article
http://dx.doi.org/10.5478/MSL.2015.6.2.38

Identification of Degradation Products in the Phosphodiesterase (PDE-4) Inhibitor Roflumilast Using High Resolution Mass Spectrometry and Density Functional Theory Calculations  

Paul, Saroj Kumar (Department of Chemistry, Institute of Technical Education and Research (ITER), Siksha 'O' Anusandhan University, Bhubaneswar)
Dash, Upendra N. (Department of Chemistry, Institute of Technical Education and Research (ITER), Siksha 'O' Anusandhan University, Bhubaneswar)
Publication Information
Mass Spectrometry Letters / v.6, no.2, 2015 , pp. 38-42 More about this Journal
Abstract
Roflumilast analogs are a group of drugs which act as selective photodiesterase (PDE-4) inhibitor for the treatment severe chronic pulmonary disease associated with chronic brochnonities. Structural identification of degradation products using high resolution mass spectrometry and theoretical investigation by density functional theory have been successfully carried out on roflumilast to identify four degradation products namely, 3,5-dichloropyridin-4-amine, N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-hydroxy benzamide, N-(3,5-dichloropyridin-4-yl)-3-(cyclopropylmethoxy)-4-(difluoromethoxy) benzamide and 3-(cyclopropylmethoxy)-N-(3,5-dichloro-1-oxidopyridin-4-yl)-4-(difluoro methoxy) benzamide, generated in alkali, acidic and oxidative conditions.
Keywords
Roflumilast; Mass Spectrometry; Degradation products; DFT;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Beghe, B.; Rabe, K. F.; Fabbri, L. M. American Journal of Respiratory and Critical Care Medicine 2013, 188, 271.   DOI
2 Giembycz, Mark, A.; Stephen K. F. Drug Design, Development and Therapy 2010, 4,147.
3 Boland, S.; Alen, J.; Bourin, A.; Castermans, K.; Boumans, N.; Panitti, L.; Vanormelingen, J.; Leysen, D.; Defert, O. Bioorg. Med. Chem. Lett. 2014, http://dx.doi.org/10.1016/j.bmcl.2014.07.016
4 ICH, International Conference on Harmonization Guidance for Industry, Impurities in New Drug Products Q3B (R2). 2006.
5 ICH, Stability Testing of New Drug Substances and Products Q1A (R2), International Conference on Harmonization, IFPMA, Geneva. 2003.
6 ICH, Impurities in New Drug Substances Q3A (R2), International Conference on Harmonization, IFPMA, Geneva. 2006.
7 Tarek, S. B.; Hytham, M. A.; Mohamed, S. M.; Hoda, G. D.; Mostafa, M. B. Bulletin of Faculty of Pharmacy Cairo University 2014, 5279.
8 Barhate, V. D.; Deosthalee, P. Indian J. Pharm. Sci. 2010, 72, 401.   DOI
9 Sun, C.; Lin, Y.; Sun, M.; Wang, D.; Chen, L. Research on Chemical Intermediates 2013, 1.
10 Zhang, H.; Lin, Y.; Li, Y.; Dong, K.; Chen, L.; Wang, D. Journal of Chemical Research 2014, 38, 507.   DOI
11 Lin, Y.; Huang, P.; Qi, H.; Chen, L.; Wang, D. Research on Chemical Intermediates 2013,39, 3111.   DOI
12 Alex, A.; Harvey, S.; Parsons, T.; Pullen, F. S.; Wright, P.; Riley, J. A. Rapid Commun. Mass Spectrom. 2009, 23, 2619.   DOI
13 Wright, P.; Alex, A.; Nyaruwata1, T.; Parsons, T.; Pullen, F. Rapid Commun. Mass Spectrom. 2010, 24, 1025.   DOI
14 Wright, P.; Alex, A.; Pullen, F. S. Rapid Commun. Mass Spectrom. 2014, 28, 1127.   DOI